Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 10/20 | 0.38 |
| ▸ | MARK3 | P27448 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31559289 | 1.00 | PGR (0.41) | PGRCNR1BACE1MARK3SLC6A4 | |
| SCHEMBL17254692 | 0.81 | PGR (0.40) | PGRMARK3SLC6A4SLC6A2RARA | |
| SCHEMBL15577510 | 0.81 | CYP19A1 (0.38) | PGRMARK3SLC6A4SLC6A2RARA | |
| SCHEMBL27421407 | 0.78 | ALDH1A1 (0.36) | PGRMARK3SLC6A4SLC6A2RARA | |
| SCHEMBL30336789 | 0.78 | PDE4A (0.42) | PGRBACE1 | |
| SCHEMBL1232150 | 0.78 | PDE4A (0.42) | PGRBACE1 | |
| SCHEMBL7703905 | 0.77 | RARA (0.56) | PGRBACE1RARARARBRARG | |
| SCHEMBL5561741 | 0.77 | MAPT (0.43) | CYP3A4 | |
| SCHEMBL4781632 | 0.77 | RARA (0.50) | MARK3RARARARBRARGCYP3A4 | |
| SCHEMBL4961767 | 0.76 | SLC6A4 (0.54) | PGRMARK3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3010914-B1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-9616053-B2 | Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-04-11 | — | — | US | disclosed |
| CN-104619701-B | For treating 2-oxo-2 of CNS disease, 3-Dihydro-indole compounds | 霍夫曼-拉罗奇有限公司 | 2016-10-19 | — | — | CN | disclosed |
| EP-2895476-B1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2016-06-22 | — | — | EP | disclosed |
| EP-3010914-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20160095844-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-04-07 | — | — | US | disclosed |
| CN-105308039-A | Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives | HOFFMANN LA ROCHE | 2016-02-03 | — | — | CN | disclosed |
| US-9221816-B2 | 2-oxo-2,3-dihydro-indoles for the treatment of CNS disorders | HOFFMANN LA-ROCHE INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150284386-A1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2895476-A1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-La Roche AG (CH) | 2015-07-22 | — | — | EP | disclosed |
| CN-104619701-A | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders | HOFFMANN LA ROCHE | 2015-05-13 | — | — | CN | disclosed |
| WO-2014202493-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014040969-A1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160095844-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | HTR2C, OPRD1, DRD3 | PGR 775/4885CNR1 72/4885BACE1 2310/4885 |
| US-20150284386-A1 | 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS | HCRTR2, TPH2, CNR2 | PGR 2049/4885CNR1 10/4885BACE1 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.